Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica Bauman, Lucian R. Chirieac, Thomas A. D'Amico, Malcolm M. Decamp, Thomas J. Dilling, Michael Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Leah J. LeischRogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Research output: Contribution to journalReview articlepeer-review

981 Scopus citations


This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Original languageEnglish (US)
Pages (from-to)504-535
Number of pages32
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number4
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology'. Together they form a unique fingerprint.

Cite this